Celldex Therapeutics, Inc. (CLDX) vs Immunome, Inc. (IMNM)
A side-by-side comparison of Celldex Therapeutics, Inc. and Immunome, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CLDX
Celldex Therapeutics, Inc.
$31.14HealthcareDelayed quote: Oct 6, 2026, 3:00 PM EDT
IMNM
Immunome, Inc.
$19.90HealthcareDelayed quote: Oct 6, 2026, 3:00 PM EDT
Total return — CLDX vs IMNM
growth of $100 · dividends reinvested · last 6yCLDX +169.6% (+18.0%/yr)IMNM +57.4% (+7.9%/yr)CLDX compounded faster over this window
CLDX IMNM
CLDX vs IMNM: by the numbers
- •CLDX is the larger company ($2.07B vs $1.90B market cap).
- •Both run net losses; IMNM's is the smaller (-3059.99% vs -268385.71% net margin).
Metrics side by side
Valuation
| Metric | CLDX | IMNM |
|---|---|---|
| P/S ratio | 18500.07 | N/A |
| P/B ratio | 2.90 | 3.62 |
Profitability
| Metric | CLDX | IMNM |
|---|---|---|
| Gross margin | 100.00% | 57.43% |
| Operating margin | -19160.00% | -3084.76% |
| Net margin | -268385.71% | -3059.99% |
| ROE | -42.07% | -48.43% |
| ROIC | -45.19% | -51.06% |
Growth (annualized)
| Metric | CLDX | IMNM |
|---|---|---|
| Revenue CAGR (5Y) | -58.05% | N/A |
| Total return CAGR (5Y) | -10.28% | 2.88% |
Frequently asked
- How have CLDX and IMNM total returns compared?
- Over the past 5 years, CLDX delivered -10.28% and IMNM delivered 2.88% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.